Meilleurs médecins de sarcome d'Ewing à l'étranger — Page 2

Le Dr Mahmoud M. El Zembely dirige le département d'oncologie pédiatrique du Shefaa Al Orman Cancer Center. Il est spécialiste en oncologie pédiatrique et en hématologie maligne. Le Dr El Zembely a effectué un fellowship clinique en transplantation de moelle osseuse pédiatrique à la Seattle Cancer Care Alliance. Il traite divers cancers de l'enfant, notamment la leucémie, le lymphome et le neuroblastome.

• Traite tous les types de leucémie infantile, ainsi que les lymphomes hodgkiniens et non hodgkiniens.
• Traite les tumeurs solides telles que le néphroblastome, le rhabdomyosarcome et les cancers rares de l'enfant.
• Réalise des transplantations de moelle osseuse allogéniques et autologues chez les patients pédiatriques.
• Travaille dans un centre accrédité par l'ESMO qui traite 6 000 patients par an.

Le Dr Raanan Berger est directeur du centre de cancérologie du Sheba Medical Center. Il a été classé parmi les « Meilleurs médecins » par Forbes Israël en 2025. Le Dr Berger est spécialisé en oncologie génito-urinaire et traite les tumeurs complexes de la prostate par radiothérapie. Il a effectué un stage postdoctoral au Dana-Farber/Harvard Cancer Institute.

• Dirige l'unité de recherche clinique axée sur l'oncologie moléculaire.
• Co-auteur de plus de 20 articles évalués par des pairs sur le cancer de la prostate et les mutations BRCA.
• Membre de l'American Society of Clinical Oncology (ASCO).
• Pratique la thérapie systémique et la radiothérapie dans un hôpital classé parmi les 10 meilleurs au monde.

Le Dr Iris Kventsel est hémato-oncologue pédiatrique et spécialiste des greffes de moelle osseuse au centre médical Sheba. Elle traite les sarcomes infantiles tels que le sarcome d'Ewing et l'ostéosarcome à l'hôpital pour enfants Edmond et Lily Safra. Le Dr Kventsel intègre des thérapies ciblées et des traitements cellulaires pour les cancers pédiatriques complexes. Elle fait partie du corps enseignant de la faculté de médecine de l'université de Tel Aviv.

• Spécialisée dans la greffe de moelle osseuse et la thérapie par cellules CAR-T pour les patients pédiatriques.
• Recherche sur la prédisposition génétique au cancer, notamment le syndrome de Li-Fraumeni et les gènes de susceptibilité.
• Publie dans des revues majeures sur la biologie des cellules souches et l'oncologie chirurgicale (HIPEC).
• Travaille au centre médical Sheba, classé parmi les 10 meilleurs hôpitaux du monde.

Le Dr Netanel Meushar dirige le service d'oncologie osseuse du centre médical Rambam.

• Spécialisé dans le traitement du cancer des os
• Expérimenté dans la gestion de cas complexes de sarcome
• Travaille dans un centre médical de premier plan en Israël

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

La Prof. Myriam Ben Arush est une spécialiste reconnue internationalement en oncologie pédiatrique et en transplantation de moelle osseuse, dirigeant la division pédiatrique de l'hôpital pour enfants Ruth Rappaport.

• Lauréate du prix du ministère de la Santé pour ses travaux exceptionnels
• Chevalier de la Légion d'honneur en France
• Nommée l'un des médecins les plus attentionnés au monde par l'Association médicale mondiale
• Membre du Children’s Oncology Group aux États-Unis et de sociétés européennes de cancérologie

Le Prof. Onder Ofluoglu possède d'expérience médicale, avec une formation spécialisée en tumeurs osseuses et des tissus mous à l'Université de Pennsylvanie et à l'Université de Californie.

• Spécialisé exclusivement en chirurgie oncologique orthopédique
• Formé à la chirurgie d'Ilizarov au Centre scientifique Ilizarov en Russie
• Auteur ou co-auteur de plus de 50 documents scientifiques
• Membre de la Connective Tissue Oncology Society et de sociétés européennes d'orthopédie

Avec plus de _doctor_9338_années_ d'expérience en hématologie et oncologie pédiatrique, le Pr Dogru est spécialisé dans les cancers complexes de l'enfant au sein de l'hôpital universitaire Biruni.

• Formation spécialisée en oncologie pédiatrique à l'Université d'Istanbul
• Expertise en transplantation de moelle osseuse
• Membre de l'organisation européenne de transplantation de moelle osseuse
• Postes de professeur adjoint dans plusieurs universités prestigieuses

Le Dr Apak est spécialisé en hématologie et oncologie pédiatrique, avec une vaste expertise en transplantation de moelle osseuse et en thérapie par cellules CAR-T à l'hôpital universitaire Biruni.

• Plus de _doctor_6792_années_ à la tête de la division d'hématologie-oncologie pédiatrique de l'université d'Istanbul-Cerrahpaşa
• A publié 75 articles internationaux sur les traitements en oncologie pédiatrique
• Rédacteur adjoint de la revue Turkish Pediatrics Archives
• Membre du conseil d'administration de la Société turque de pédiatrie et de l'Association turque de médecine de l'adolescent

Chirurgien orthopédique

La Prof. Dr. Suna Emir a obtenu son diplôme de la faculté de médecine de l'Université Hacettepe en 1989. Elle a terminé sa résidence en pédiatrie à l'Université Hacettepe de 1990 à 1995. En 2001, elle a terminé sa sous-spécialité en oncologie pédiatrique à l'Institut d'oncologie de l'Université Hacettepe. Elle est devenue professeure associée en 2004. De 2004 à 2009, elle a travaillé à l'hôpital de formation et de recherche en santé et maladies infantiles d'Ankara Dışkapı et y a fondé la clinique d'oncologie pédiatrique. En 2009, elle a occupé le poste de chef adjointe du service d'oncologie pédiatrique. De 2009 à 2016, elle a été responsable de la formation en hématologie-oncologie pédiatrique à l'hôpital de formation et de recherche en santé et maladies infantiles, hématologie et oncologie d'Ankara. Depuis 2019, elle est professeure et membre fondatrice de la faculté de santé et maladies infantiles de l'Université Atilim.

Elle est experte en pédiatrie générale et en hématologie-oncologie pédiatrique. Elle est active dans la formation des résidents et des sous-spécialités. Ses intérêts cliniques incluent les maladies infantiles de la naissance à 18 ans, les lymphomes, les tumeurs solides, la greffe de moelle osseuse autologue, l'anémie, les troubles de la coagulation, les maladies héréditaires du sang, les hémangiomes et autres tumeurs bénignes, ainsi que les ganglions lymphatiques hypertrophiés.

Chef du Centre d'Oncologie de la Charité – Le Dr Keilholz apporte une expertise de haut niveau dans les cas de cancer complexes.

• Spécialisée en oncologie avec un accent sur le sarcome d'Ewing
• Dirige l'un des principaux centres d'oncologie de Berlin

Plus de _doctor_3339_années_ de spécialisation en oncologie pédiatrique – Le Dr López-Ibor dirige l'unité d'hématologie et d'oncologie pédiatrique à HM Montepríncipe.

• Experte dans le traitement des tumeurs osseuses comme le sarcome d'Ewing
• Formée à l'Université du Maryland, un centre de premier plan en oncologie pédiatrique aux États-Unis
• Ancienne chef du service d'oncologie pédiatrique à l'Hospital Universitario Clínica San Rafael
• Auteure de nombreuses publications dans des revues nationales et internationales

Angelika Eggert est chef du département d'oncologie pédiatrique à la Charité, l'un des plus grands hôpitaux universitaires d'Europe.

• Dirige un département majeur dans un hôpital européen de premier plan
• Se concentre exclusivement sur le traitement du cancer pédiatrique
• Accès aux derniers essais cliniques pour les jeunes patients

Le Dr Kharya, hématologue-oncologue pédiatrique, est spécialisé dans les greffes de moelle osseuse pour les cancers de l'enfant aux Artemis Hospitals.

• Expertise en hématologie et oncologie pédiatrique
• Spécialisé dans la greffe de moelle osseuse
• Axé sur le traitement des cancers de l'enfant

Le professeur Demirkaya est spécialisé en oncologie pédiatrique avec 27 années d'expérience dans le sarcome d'Ewing à l'hôpital Medicana Bursa.

• Formé au programme de résidence en oncologie pédiatrique de l'Université Bursa Uludag
• Ancien membre du corps professoral de la faculté de médecine de l'Université Bursa Uludag
• A travaillé au centre de pédiatrie, d'hématologie, d'oncologie et de transplantation de moelle osseuse GATA
• Professeur actuel d'oncologie pédiatrique à Medicana Bursa

Le Dr Shruti Kate est spécialisée dans le sarcome d'Ewing avec une expertise en immunothérapie et en thérapie métronomique pour les cancers avancés. Elle a été formée au Tata Memorial Hospital, un centre de cancérologie de premier plan.

• Diplôme en oncologie médicale du Tata Memorial Hospital
• Membre de l'ASCO, de l'ESMO et d'autres sociétés d'oncologie prestigieuses
• A présenté des recherches sur le cancer du poumon au WCLC 2018
• Expérience dans le traitement des tumeurs pédiatriques et des tumeurs solides

Le Dr Blanca Lopez Ibor dirige l'unité d'hématologie et d'oncologie pédiatrique chez HM Hospitales, avec plus de 31 années d'expérience en oncologie pédiatrique.

• Spécialisée dans les troubles hématologiques et cancéreux chez les enfants et les adolescents
• Consultante pour l'OMS et l'UNESCO en oncologie pédiatrique
• Présidente de la Fundación Jaime Alonso Abruña, qui aide les enfants souffrant de problèmes de santé graves
• Membre de la Société Internationale d'Oncologie Pédiatrique (SIOP)
• Conférencière à l'Université Complutense de Madrid et à l'Université CEU San Pablo